SPARC/Sec/SE/2018-19/029 4th September 2018

To
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001

Ref: *Scrip Code: NSE: SPARC; BSE: 532872*
Sub: *Investor Presentation—Update on NCE & NDDS programs*

Dear Sir/ Madam,

Further to out letter No. SPARC/Sec/SE/2018-19/011 dated 4th July 2018 on the subject, please find enclosed a copy of the presentation by the Company providing update on NCE & NDDS programs, which is self-explanatory.

You are requested to kindly take the same on your record & disseminate the information through your website.

Yours faithfully,
For **Sun Pharma Advanced Research Company Limited**

Debashis Dey
Company Secretary

Encls: A/a.

sparc

Update on R&D Pipeline

4th September 2018

BSE:532872 • NSE: SPARC • BLOOMBERG: SPADV@IN • REUTERS: SPRC.BO • CIN:L73100GJ2006PLC047837

Disclaimer

This presentation and its contents are confidential and should not be distributed, published or reproduced, in whole or part, or disclosed by recipients directly or indirectly to any other person. Any failure to comply with these restrictions may constitute a violation of applicable laws. Accordingly, any persons in possession of this presentation should inform themselves about and observe any such restrictions. This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. This presentation should not be relied upon as a recommendation or forecast by Sun Pharma Advanced Research Company Limited ("Company"). Please note that the past performance of the Company is not, and should not be considered as, indicative of future results. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward looking statements. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoters or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertakes no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefor. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

Agenda

1 **SPARC Strategy & Key Growth Drivers**
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 **S1PR1 Agonist**
Kristine Nograles – V.P. Dermatology & Rheumatology

5 **Extended Ocular Retention**
Hany Michail – V.P. Ophthalmology

6 **Nanoformulations & Long Acting Depots**
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 **Pipeline Build-up Strategy**
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 **Q&A**

Agenda

1 **SPARC Strategy & Key Growth Drivers**
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 **S1PR1 Agonist**
Kristine Nograles – V.P. Dermatology & Rheumatology

5 **Extended Ocular Retention**
Hany Michail – V.P. Ophthalmology

6 **Nanoformulations & Long Acting Depots**
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 **Pipeline Build-up Strategy**
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 **Q&A**

SPARC's Journey

Poised to reach important milestones….



- SPARC responded to US FDA CRLs indicating facility compliance and readiness, resetting the regulatory clock for approval
  - Xelpros™ : PDUFA date – Nov'18
  - Elepsia™ XR : PDUFA date – Jan'19

CRL = Complete Response Letter, PDUFA = Prescription Drug User Fee Act; PDP – 716 = Brimonidine OD, SDN – 037 = SDP – 037 FY = Financial Year
US FDA = United States Food & Drug Administration Taclantis is provisionally approved trade name by US FDA

…marking the conclusion of our initial set of delivery solutions



- Baclofen GRS
  - Pivotal studies did not meet the primary end point
  - Met several clinically significant secondary end-points (E.g.: Spasm Frequency, SGIC, etc.)
  - Plan to submit additional registration studies while exploring opportunities to partner
- Salmeterol – Fluticasone DPI
  - Completed regulatory consultations with multiple European regulatory agencies
  - Registration pathway may involve additional BE and clinical endpoint studies
  - Challenging commercial and reimbursement environment
  - Currently exploring partnership opportunities

PDP – 716 = Brimonidine OD, SDN – 037 = SDP – 037, SGIC: Subject Global Impression of Change DPI = Dry Powder Inhaler BE = Bioequivalence

Key takeaways from our initial programs

- Need for enhanced translational rigor
- Challenging reimbursement environment – Need for balanced risk profile
- Importance of versatile, multi-indication platforms
- Narrow therapeutic focus
- Prudent risk raking

Abl kinase inhibitors	▪ SCO – 088: Chronic Myeloid Leukemia ▪ SCC – 138: Parkinson's Disease ▪ SCO – 125: Chronic Myeloid Leukemia
S1PR1 agonist	▪ SCD – 044: Autoimmune disorders
Abuse & overdose deterrent formulations	▪ SDN – 021: Oral multi-pill abuse deterrence ▪ SDN – 118: Oral multi-pill overdose prevention
Extended ocular retention	▪ PDP – 716: Glaucoma ▪ SDN – 037: Ocular pain & inflammation
Nanoformulations & long acting depots	▪ SDE – 124: Type 2 diabetes ▪ SDD – 098: Acne

Platforms under early clinical development will drive our portfolio value and resource allocation in the short/medium term

SCO – 088 = K0706 CML, SCC – 138 = K0706 Parkinson's Disease, SCO – 125 = K0954, PDP – 716 = Brimonidine OD, SDD – 098 = Minocycline topical SDN – 037 = SDP – 037

Possible value inflection points & resource allocation

A snapshot of next 24 months



Data read out, SCO – 088 = K0706 CML, SCC – 138 = K0706 Parkinson's Disease, SCO – 125 = K0954 CML, PDP – 716 = Brimonidine OD, SDD – 098 = Minocycline topical
SDN – 037 = SDP – 037

We will continue to be in the investment mode in the medium term



Data read out, SCO – 088 = K0706 CML, SCC – 138 = K0706 Parkinson's Disease, SCO – 125 = K0954 CML, PDP – 716 = Brimonidine OD, SDD – 098 = Minocycline topical
SDN – 037 = SDP – 037

SPARC R&D priorities

Execute on SPARC clinical portfolio on schedule and budget to achieve financial sustainability

Increase the **rigor of portfolio decision making** to ensure quality of assets transitioning from pre-clinical to clinical development

Leverage **computational capabilities and external strategic partnerships** to grow discovery funnel

Continue **to invest in SPARC operational model** build up

SPARC will continue to focus on building versatile platforms which can advance the standards of care meaningfully in chosen therapeutic segments

Dedicated research facility at Savli, Vadodara

- Dedicated, modern campus with world class infrastructure
- Augmenting research capabilities with state of the art technology and equipment
- Plan to shift to new facility by Q4 FY19

Agenda

1 SPARC Strategy & Key Growth Drivers
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 Abl Kinase Inhibitor
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 S1PR1 Agonist
Kristine Nograles – V.P. Dermatology & Rheumatology

5 Extended Ocular Retention
Hany Michail – V.P. Ophthalmology

6 Nanoformulations & Long Acting Depots
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 Abuse & Overdose Deterrent Platform
Yashoraj Zala – V.P. Formulation Development

8 Pipeline Build-up Strategy
Nitin Damle – Sr. V.P. Innovation

9 Competitive Landscape – Key Programs
Jaydeep Issrani – G.M. Business Development

10 Q&A

Financial summary

(INR mn)	FY18	FY17	FY16	FY15	FY14
Total Income	832	1,947	1,642	1,588	1,770
Total Expenses	3,292	3,137	2,342	1,983	1,427
Exceptional Item	490	-	-	-	-
Profit (Loss) after Tax	(1,970)	(1,190)	(700)	(395)	303
Total Comprehensive Income (Net of tax)	(1,984)	(1,195)	N.A.	N.A.	N.A.

Liquidity Status

- Cash and cash equivalents INR 1,764 mn as on 31-Aug-18
- Higher working capital need due to GST

Financial Summary

- Expected cash outflows
  - Increased number of clinical programs
  - Higher operating expenses
  - Refurbishing cost of new facility at Savli
- Expected cash inflows
  - Raised INR 5,000 mn through Preferential Issue of Warrants (70% received, INR 1,500 mn to be received in Jan-19)
  - Milestone payments upon approval of Xelpros™ and Elepsia™
  - Out-licensing of Taclantis™, if pivotal BE study outcome is positive

BE = Bioequivalence

Agenda

1 SPARC Strategy & Key Growth Drivers
Anil Raghavan – CEO

2 Financial Highlights
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 S1PR1 Agonist
Kristine Nograles – V.P. Dermatology & Rheumatology

5 Extended Ocular Retention
Hany Michail – V.P. Ophthalmology

6 Nanoformulations & Long Acting Depots
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 Abuse & Overdose Deterrent Platform
Yashoraj Zala – V.P. Formulation Development

8 Pipeline Build-up Strategy
Nitin Damle – Sr. V.P. Innovation

9 Competitive Landscape – Key Programs
Jaydeep Issrani – G.M. Business Development

10 Q&A

SCO – 088

Encouraging preliminary efficacy and safety observed

- Effective against BCR-ABL and its mutants, including T315I mutation
- Multiple Ascending Dose (MAD) study ongoing in CML patients
  - Completed 5 dose escalations
  - PK supports once-a-day dosing
  - 1st subject continuing treatment, completed 17 cycles



SCO – 088 = K0706 CML, CML = Chronic Myeloid Leukemia CP = Chronic phase AP = Accelerated phase BP = Blast phase Ph+ALL = Philadelphia positive Acute Lymphocytic Leukemia

SCO – 088

Haematological response in CML patients



- Haematological response rate ~80% in subjects enrolled
- No cardiovascular events reported till date
- Transient self-limiting grade 1/2 neutropenia reported in one patient only

SCO – 088 = K0706 CML, CML = Chronic Myeloid Leukemia, C3D28 = Cycle 3 Day 28. C4D1 = Cycle 4 Day 1, C6D28 = Cycle 6 Day 28, C7D1 = Cycle 7 Day 1

SCO – 088
Development status update

- Plan to complete MAD study by Q4 FY19
- Phase 2 pivotal efficacy study
  - Single arm, open label, efficacy study in 150 subjects failed on ≥ 3 TKIs
  - Protocol submission to US FDA by Q2 FY19
  - Study initiation by Q3 FY19

SCO – 088 = K0706 CML, CML = Chronic Myeloid Leukemia, TKI = Tyrosine Kinase Inhibitor, US FDA = United States Food & Drug Administration MAD = Multiple Ascending Dose

Parkinson's Disease

Increasing incidence due to the aging population



- Over 1 mn people living with Parkinson's Disease in the US^
- Expected to grow to ~1.35 mn by 2022 with about 60,000 new patients diagnosed every year
- No disease modifying therapy available
  - Currently available therapies provide symptomatic relief only

*IQVIA MAT June 2018 ^Parkinson's Disease Foundation - http://www.pdf.org/parkinson_statistics

SCC – 138

Supporting pre-clinical data in Parkinson's Disease

Pre-clinical development

Therapeutic potential in α-synuclein PFF induced model

Role of SCC – 138 in human IPSC-derived neurons

1) Augmenting Parkin activity
2) Modulating autophagic flux and α-synuclein metabolism
3) Altering α-synuclein inclusions

Therapeutic potential in AAV1/2 α-synuclein rat model

Effect of 3-day vs. 14-day treatment of the SPARC c-Abl inhibitors on the autophagic flux.



SCC – 138 = K0706 Parkinson's Disease, SCO – 125 = K0954 PFF = Pre Formed Fibrils IPSC = Induced Pluripotent Stem Cells AAV = Adeno Associated Virus

SCC – 138
1st in class disease modifying treatment

- Orally active, disease modifying treatment with potential neuro-protective activity
- Inhibits Abl and Fyn kinase – relevant to neurodegeneration
- Completed 6 dose cohorts in Phase 1 PD patients study
- No significant adverse events observed in highest studied dose level*
- Preliminary human PK data demonstrates drug presence in CSF



*Data available up to 48mg cohort, SCC – 138 = K0706 Parkinson's Disease, CSF = Cerebrospinal fluid PD = Parkinson's Disease

SCC – 138
Development status update

- MAD study on-going; plan to add higher dose levels
- Phase 2 PoC to be initiated in PD patients by Q3 FY19 at multiple centres across North America, Asia and Europe

Agenda

1 **SPARC Strategy & Key Growth Drivers**
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 **S1PR1 Agonist**
Kristine Nograles – V.P. Dermatology & Rheumatology

5 **Extended Ocular Retention**
Hany Michail – V.P. Ophthalmology

6 **Nanoformulations & Long Acting Depots**
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 **Pipeline Build-up Strategy**
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 **Q&A**

SCD – 044

Selective S1PR1 agonist for autoimmune diseases

- SPARC is developing a novel orally bioavailable, potent and selective S1PR1 agonist in collaboration with Bioprojet, France
- S1PR1 agonists cause diminished migration of lymphocytes out of lymphoid tissues leading to decrease in circulating lymphocytes thereby reducing inflammation
- Encouraging results in animal models of autoimmune diseases, including psoriasis
- First-in-human study is currently ongoing to establish safety profile in healthy volunteers

S1PR1 = Sphingosine-1-phosphate receptor 1

SCD – 044
First-in-Human Study is well underway

- Multi-part study in healthy volunteers
  - **Part 1**: Single ascending dose study completed
    - 6 dose groups evaluated compared to placebo
    - Decrease in lymphocyte counts was observed at all dose levels evaluated
    - Established a maximum tolerated dose
    - Terminal elimination half-life ($t_{1/2}$) of ~34 h, independent of dose
  - **Part 2**: Food effect study completed
  - **Part 3**: Multiple ascending dose study ongoing



*Phase 1 part 1 SAD study, 2 mg dose.

SCD – 044
Development status update

- Planned completion of Phase 1 study by Q1 FY20
- Phase 2 study initiation anticipated by Q1 FY20
  - Indications under consideration include Psoriasis, Inflammatory Bowel Diseases, Atopic Dermatitis & others

Agenda

1 **SPARC Strategy & Key Growth Drivers**
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 **S1PR1 Agonist**
Kristine Nograles – V.P. Dermatology & Rheumatology

5 **Extended Ocular Retention**
Hany Michail – V.P. Ophthalmology

6 **Nanoformulations & Long Acting Depots**
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 **Pipeline Build-up Strategy**
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 **Q&A**

PDP – 716

Novel once-a-day eye drops for Glaucoma

- Existing formulations of Brimonidine, an α2 adrenergic agonist, are administered TID in the second line treatment of Glaucoma
- TID dosing often results in lower treatment adherence rates in patients*
- SPARC is developing improved formulation of Brimonidine for once-a-day dosing utilizing its proprietary TearAct™ technology



Drug release from nanoclusters by tear salts

IOP = Intra Ocular Pressure, *J Glaucoma. 2011 Oct;20(8):502-8; TID = Three times-a-day, PDP – 716 = Brimonidine OD

PDP – 716

Phase 2 data supports once-a-day dosing

- Proof of concept demonstrating equivalence to Alphagan® P dosed TID was completed in human trial
- Met pre-specified clinical equivalence efficacy criteria compared to Alphagan® P TID at all time points
- No new adverse events reported



IOP = Intra Ocular Pressure, PDP – 716 = Brimonidine OD, TID = Three times-a-day

PDP – 716
Development status update

- IND submitted in Q4 FY18
- US FDA alignment on single, active controlled Phase 3 study with Alphagan® P as a comparator to support NDA submission
- Phase 3 study initiated in Q1 FY19
  - Target enrolment of 666 subjects
  - Recruitment at ~27 sites across the US
- NDA submission planned by Q4 FY20

PDP – 716 = Brimonidine OD, IND = Investigational New Drug, US FDA = United States Food & Drug Administration, NDA = New Drug Application

SDN – 037

Improved ocular steroid with reduced dosing frequency

- Currently marketed steroid eye drops are approved for QID dosing
- Additionally, marketed products have hazy/milky appearance which may blur the vision upon administration
- SPARC is developing novel formulation of an existing steroid utilizing its Micellar technology
- Differentiated topical steroid eye drops with BID dosing & clear/transparent appearance is expected to provide meaningful benefit to the patients



QID = Four times- a- day, BID = Two times- a- day SDN – 037 = SDP – 037

SDN – 037
Development status update

- US FDA alignment on single, vehicle controlled Phase 3 study to support NDA submission
- Phase 3 study initiated in Q1 FY19
  - Target enrolment of 386 subjects
  - Recruitment at ~15 sites across US
- NDA submission planned by Q2 FY20

Agenda

1 **SPARC Strategy & Key Growth Drivers**
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 **S1PR1 Agonist**
Kristine Nograles – V.P. Dermatology & Rheumatology

5 **Extended Ocular Retention**
Hany Michail – V.P. Ophthalmology

6 **Nanoformulations & Long Acting Depots**
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 **Pipeline Build-up Strategy**
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 **Q&A**

Taclantis™
Establishing bio-equivalence to Abraxane®

Novel formulation of paclitaxel using SPARC's proprietary Nanotecton™ platform technology



- Pivotal BE study fully enrolled
  - 142 patients randomized
  - 99 evaluable patients
  - No hypersensitivity reactions observed
- Data read out expected by Q3 FY19
- Planned NDA filing by Q4 FY19

BE study = Bioequivalence study NDA = New Drug Application

SDE – 124

Long acting formulation of GLP–1 receptor agonist

- 21 mn diagnosed cases of type 2 diabetes in the US#; estimated 1.5 mn new cases diagnosed annually^
- GLP-1 receptor agonists reported annual sales of ~$9 bn with 39% YoY growth*
- Currently marketed reference product available as a daily injection
- Developed long acting, subcutaneous injection for self administration
- Nanostructured gel; harnesses drug and excipient's self-assembling property
  - Drug release by erosion
  - Employs GRAS excipients



*IQVIA Mat June 2018 National Diabetes Statistics Report 2017 #Prevalence of Diagnosed Diabetes in Adults by Diabetes Type — United States, 2016 Weekly / March 30, 2018 / 67(12);359–361 GLP -1 = Glucagon–like Peptide – 1 Zheng SL et.al. JAMA. 2018;319(15):1580-1591, GRAS : Generally regarded as safe, GLP 1 = Glucagon Like Peptide 1

SDE – 124

Encouraging efficacy in pre-clinical setting

Comparative PK profile in SD rats



Comparative HbA1C profile in Fatty-Zucker rats



- Therapeutically effective levels maintained for desired duration in SD rats
- Significant reduction in %HbA1C was observed after multiple SC injections

*Extrapolated to expected human equivalent dose, Two way ANOVA followed by Bonferroni post test, ***p<0.001 as compared to Placebo, $$p<0.01 as compared to Trulicity
SD rats = Sprague Daeley rats SC = Sub-cutaneos

SDE – 124
Development status update

- Prototype formulation ready; short term stability study ongoing
- Pre-IND meeting with US FDA completed
- IND enabling toxicology studies planned to be initiated by Q3 FY19
- IND submission by Q3 FY20
- Phase 1 human PoC study initiation by Q4 FY20

US FDA = United States Food & Drug Administration IND = Investigational New Drug PoC = Proof of concept

SDD – 098
Development status update

- According to AAD, more than 5 mn people seek medical treatment for acne and has significant impact on productivity for affected individuals
- SPARC is developing novel topical formulation of Minocycline designed to reduce systemic side-effects associated with oral dosing
- Phase 1 enabling toxicity study ongoing
- Pre-IND meeting completed with US FDA
- IND filing expected by Q4 FY19

SDD-098 = Minocycline topical AAD = American Academy of Dermatology IND = Investigational New Drug NDA = New Drug Application
US FDA = United States Food & Drug Administration

Agenda

1 SPARC Strategy & Key Growth Drivers
Anil Raghavan – CEO

2 Financial Highlights
Chetan Rajpara – CFO

3 Abl Kinase Inhibitor
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 S1PR1 Agonist
Kristine Nograles – V.P. Dermatology & Rheumatology

5 Extended Ocular Retention
Hany Michail – V.P. Ophthalmology

6 Nanoformulations & Long Acting Depots
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 Pipeline Build-up Strategy
Nitin Damle – Sr. V.P. Innovation

9 Competitive Landscape – Key Programs
Jaydeep Issrani – G.M. Business Development

10 Q&A

SDN – 021

Potential to deter oral multiple pill abuse

- 187 mn prescriptions generated for IR opioids with estimated value of ~$2 bn*
- 66% of the abusers prefer IR formulations due to ease of manipulation^
- SPARC developed IR opioid formulation with abuse deterrent properties for oral, nasal and IV abuse
- Includes presence of an aversive agent to further deter abuse if tampered
- Encouraging results in Category I *in-vitro* tamperability evaluation



*IQVIA MAT June 2018, ^Postgraduate Medicine, 2016, 128:1, 85-96 IR = Immediate release IV = Intra venous

SDN – 021
Multiple pill abuse deterrence – main driver to adoption*

SDN – 021 Adoption drivers*



SDN – 021 Perceived key benefit *



87% of physicians see oral multi-pill abuse deterrence as a driver to utilize SDN-021*

75% of payers view oral multi-pill abuse deterrence as a major benefit*

Q: What are the main drivers of your utilization? (n=44)

Q: What are the major benefits of SDN-021? (n=12)

*Based on primary market research conducted on behalf of SPARC by third party in the US

SDN – 021
Development status update

- Pilot Human Abuse Liability (HAL) study ongoing
  - Primary endpoint: Drug Liking – E_{max}
  - Cohort A recruitment completed
  - Cohort B recruitment ongoing
  - Topline data expected by Q3 FY19
- Phase 3 clinical study planned in concurrence with US FDA guidance; planned initiation by Q3 FY19
- Pivotal Category 1 studies planned in Q1 FY20

US FDA = United States Food & Drug Administration E_{max} = Maximum effect

SDN – 118

Addressing prescription drug overdose

- Suicide, one of the top 10 leading causes of death in the US
- SPARC has developed an anti-depressant product based on overdose prevention technology platform
- Technology works to curb release on ingestion of multiple pills either intentionally or accidentally
- Single dose preliminary PK studies encouraging



PK = Pharmaco kinetic Morbidity and Mortality Weekly Report, Vol. 61, No. 6, September 2012

SDN – 118

Overdose prevention technology



- Mechanism of release from one pill
  - Quantity of pH modulator released from 1 pill does not affect the microenvironment of stomach
  - Polymer solubilizes
  - Therapeutic dose delivered
- Mechanism of release from multiple pills
  - Quantity of pH modulator released from multiple pills changes the microenvironment of stomach
  - Changed microenvironment restricts solubility of polymer and thus drug release
  - Harm due to multiple pill overdose may thus be reduced

SDN – 118
Development status update

- Pre-IND advice received from the US FDA
- IND filing planned in Q3 FY19
- Overdose PoC PK studies planned in Q4 FY19

IND = Investigational New Drug NDA = New Drug Application US FDA = United States Food & Drug Administration PoC = Proof of Concept

Agenda

1 **SPARC Strategy & Key Growth Drivers**
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 **S1PR1 Agonist**
Kristine Nograles – V.P. Dermatology & Rheumatology

5 **Extended Ocular Retention**
Hany Michail – V.P. Ophthalmology

6 **Nanoformulations & Long Acting Depots**
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 **Pipeline Build-up Strategy**
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 **Q&A**

Early stage pipeline building strategy

- Internal ideation
  - Chase validated drug targets in select therapeutic areas
  - Leverage capabilities in complex drug delivery systems to pursue commercially attractive 505(b)(2) opportunities
- External innovation network
  - Partnerships with leading global academic centers to source promising early stage innovative science/biology
  - Pursue novel first-in-class or best-in-class opportunities with high unmet clinical needs
- Exploratory programs
  - Augmenting capabilities to pursue new treatment modalities outside of traditional small molecule drug discovery



Attacking treatment resistance in cancer

- Fast follower approach in a clinically and commercially validated space
- A number of molecularly targeted therapies against the indications of interest
- Emerging evidence of the development of resistance to targeted therapies
  - Resistance often attributed to mutations in the molecular targets rendering the targeted therapeutic being chased ineffective
  - Resistance due to adaptation to an alternative signaling pathway(s)
- Resistance to hormonal therapies against carcinomas of breast and prostate
  - ERα targeting by tamoxifen or fulvestrant
  - AR targeting by enzalutamide or apalutamide
- Targeted therapy for B lymphoid malignancies
  - Targeting ibrutinib/acalabrutinib resistance

Neurodegeneration

- A common pathway of neuronal death irrespective of disease-specific misfolded protein inclusions in distinct neurodegenerative diseases



- Autophagy, a process by which cells try to eliminate nonfunctional misfolded proteins and organelles
- Inability of neurons to mediate autophagy often leads to neurodegeneration
- SPARC's emphasis is on prevention of neuronal death in these neurodegenerative diseases

SOD = Super oxide dismutase TDP43 = Transactive response DNA binding protein 43 ALS = Amyotrophic lateral sclerosis

Update on collaborations

- Pursue active collaborations with global academic centres and research institutes
- Unique academic partnering proposition for significant value creation
  - Cash investment
  - In-kind contribution leveraging internal infrastructure in preclinical & clinical development
- Flexible partnering structures
  - Standard in-licensing
  - Grant funding with option to license
  - Material transfer with option to license
  - Sponsored research

SPARC – Washington University Collaboration

- SPARC partnered with Skandalaris Center of Washington University, St. Louis, US
  - Identifying translational inventions and advancing them towards commercialisation
- SPARC supported Skandalaris Center's LEAP (Leadership in Entrepreneurial Acceleration Program) Inventor Challenge Program
  - Up to $250,000 per program in awards every year for three (3) years
  - Additional in-kind support utilizing internal R&D capabilities at SPARC
  - Option to license IP on worldwide exclusive basis

Agenda

1 SPARC Strategy & Key Growth Drivers
Anil Raghavan – CEO

2 Financial Highlights
Chetan Rajpara – CFO

3 Abl Kinase Inhibitor
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 S1PR1 Agonist
Kristine Nograles – V.P. Dermatology & Rheumatology

5 Extended Ocular Retention
Hany Michail – V.P. Ophthalmology

6 Nanoformulations & Long Acting Depots
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 Abuse & Overdose Deterrent Platform
Yashoraj Zala – V.P. Formulation Development

8 Pipeline Build-up Strategy
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 Q&A

Taclantis™
Albumin free nanoformulation of Paclitaxel

- Over 45% of US clinicians documented hypersensitivity reactions in more than 10% patients treated with Cremophor ® based paclitaxel*
- More than 60% of US physicians view risk of hypersensitivity and ease of administration as important factors influencing choice of therapy*
- Cremophor® based formulations account for ~70% of total Paclitaxel units prescribed#
- Significant opportunity for conversion to novel formulations like Taclantis™



*Based on primary market research conducted on behalf of SPARC by third party in the US, #Internal estimates ^IQVIA MAT June 2018 (Units equivalent to 100 mg)

PDP – 716
US market opportunity

- US Glaucoma market is estimated at $ 3.0 bn in 2017*
- Brimonidine is one of the most widely prescribed anti-glaucoma drug with sales of $ 417 mn and 3.7 mn prescriptions dispensed annually*
- Brimonidine branded product commands significant market share inspite of genericization of lower strength formulation



*IQVIA MAT June 2018 PDP – 716 = Brimonidine OD

PDP – 716

Once-a-day eye drops perceived favourably by physicians

- Clear preference of physicians for PDP – 716*
- 93% of physicians would prefer to prescribe once a day eye drops
- Novel once-a-day Brimonidine eye drops expected to take meaningful market share



Q. Given a choice, which of the following eye drops of Brimonidine would you prefer to prescribe? (n=30)

* Based on primary market research conducted on behalf of SPARC by third party in the US PDP – 716 = Brimonidine OD TID = Three times-a-day

SDN – 037
US market opportunity

- Cataract causes half of all cases of blindness and affects more than 24 mn people in US with age 40 and older
- Topical steroids are standard of care for the treatment of pain & inflammation associated with cataract surgery
- US topical ocular steroid market valued at $ 750 mn with ~9 mn Rx dispensed annually*
- Currently marketed formulation cause blurring of vision and need to be dosed four times-a-day
- Novel improved steroid composition with BID dosing would provide significant compliance benefit



*IQVIA MAT June 2018 SDN – 037 = SDP – 037 BID = Two times-a-day

SCO – 088

Targeting treatment intolerance and resistance in CML

- Increasing usage of 2nd and 3rd generation TKIs
- Limited treatment options for 3rd line and beyond
- Physicians believe, the currently available therapies are inadequate for 3rd line treatment in CML#
- KOLs acknowledged the need for an agent with a reasonable toxicity profile for T315I mutation disease#



#Primary market research conducted on behalf of SPARC by third party in US. *IQVIA MAT June 2018. ^Internal Estimates, @Clin Cancer Res 2013;19:5828-5834. TKIs = Tyrosine Kinase Inhibitors CML = Chronic Myeloid Leukemia

Agenda

1 **SPARC Strategy & Key Growth Drivers**
Anil Raghavan – CEO

2 **Financial Highlights**
Chetan Rajpara – CFO

3 **Abl Kinase Inhibitor**
SiuLong Yao – Sr. V.P. Clinical Development & Operations

4 **S1PR1 Agonist**
Kristine Nograles – V.P. Dermatology & Rheumatology

5 **Extended Ocular Retention**
Hany Michail – V.P. Ophthalmology

6 **Nanoformulations & Long Acting Depots**
Ajay Khopade – V.P. Formulation Development
Yashoraj Zala – V.P. Formulation Development

7 **Abuse & Overdose Deterrent Platform**
Yashoraj Zala – V.P. Formulation Development

8 **Pipeline Build-up Strategy**
Nitin Damle – Sr. V.P. Innovation

9 **Competitive Landscape – Key Programs**
Jaydeep Issrani – G.M. Business Development

10 **Q&A**

R&D Pipeline

COPD = Chronic Obstructive Pulmonary Disease CML = Chronic Myeloid Leukemia T2DM = Type 2 Diabetes Mellitus

Thank You